Rein Therapeutics, Inc.

Rein Therapeutics maintains a fragile capital structure characterized by high liquidity risk and significant dilution pressure. As of Q1 2026, the company holds $4.4 million in cash and equivalents against total liabilities of $14.7 million, resulting in a current ratio of 0.4, which indicates that current liabilities exceed current assets. The balance sheet shows total assets of $26.3 million and total equity of $11.6 million, with a debt-to-equity ratio of 0.0, suggesting reliance on equity financing rather than traditional debt. However, the company reported a net loss of $5.8 million and operating cash flow of -$3.4 million for the quarter, underscoring its cash-burn trajectory. The diluted share count of 30.4 million is materially higher than the basic share count of 28.0 million, reflecting substantial embedded dilution from warrants, options, and convertible instruments.

Profitability metrics are deeply negative, consistent with an early-stage biotech firm. Return on equity stands at -4.30, and return on assets is -1.90, indicating that the company is destroying capital value as it invests in research and development. With zero revenue, traditional margin analysis is not applicable. The company’s economic model relies entirely on future clinical success and potential licensing or partnership deals to generate cash flows, rather than current operational profitability.

The company’s revenue mix is nonexistent, as it reports $0.0 in revenue. Its operational focus is concentrated on the development of LTI-03, a peptide therapy targeting fibrotic diseases, while development of LTI-01 and other preclinical programs has been paused due to liquidity constraints. Geographic exposure is not explicitly detailed in terms of revenue, but the company is headquartered in the United States and conducts its primary clinical and operational activities domestically, with some licensing agreements involving international entities like Harvard and Dana-Farber.

Growth trajectory is currently negative in terms of cash reserves and positive in terms of share count due to financing activities. The company has raised capital through various mechanisms, including underwritten public offerings, at-the-market offerings, and pre-paid advance agreements. The recent filing observations indicate a series of equity issuances and warrant exercises, which have increased the share count and diluted existing shareholders. The company’s ability to grow is contingent on securing additional funding to restart clinical trials for LTI-03.

Risk factors are elevated, with high liquidity and dilution risks flagged. The company has disclosed going-concern or substantial-doubt language in its filings, highlighting the uncertainty of its ability to continue operations without further capital. Key flags include the material difference between basic and diluted share counts, current liabilities exceeding current assets, and references to dilution or offering risks in source documents. The company’s reliance on third-party manufacturing and CROs adds operational risk, while the unproven nature of its drug development approach poses scientific risk.

Recent events include the company’s stock price falling below $1.00, triggering US continued-listing minimum-bid threshold concerns. The company has also engaged in multiple financing activities, including the issuance of common stock, notes payable, and warrants. Filings reference various agreements, including pre-paid advance agreements with YAIIPN Ltd and standby equity purchase agreements. The company has paused development of LTI-01 and other preclinical programs, prioritizing LTI-03, and has disclosed material weaknesses in its internal controls over financial reporting.

Rein Therapeutics, Inc. (RNTX) has recorded a notable addition to its shareholder base, marking the first analysis for the ticker with no prior basis for delta computation. This initial snapshot highlights a specific institutional activity rather than a shift from a previous state, establishing a baseline for future monitoring of the company's ownership structure. The primary signal is a new holder addition detected on June 20, 2026. According to the data, investor ID 466 acquired a position as of June 30, 2024, holding 31,285 shares. This position represents a value of $0.08666 million and constitutes a weight of approximately 0.000196% of the relevant metric, indicating a relatively small but notable entry into the company's cap table. This activity occurs within a broader context of limited market coverage and concentrated ownership. Rein Therapeutics currently has zero analyst coverage and is not a member of any major indices, suggesting a niche or early-stage market presence. The company's leadership is minimal, with only one officer reported, while its shareholder base is comprised of seven top holders, pointing to a tightly held equity structure. The significance of this new holder lies in the context of this low-coverage environment. With no analyst estimates or index membership to drive broad market attention, individual institutional moves like this addition may carry disproportionate weight in signaling interest. As the first recorded analysis for RNTX, this data point serves as the foundational reference for tracking future changes in investor sentiment and ownership concentration.

Analysts project 765.8% upside to a $10 target price, signaling strong institutional confidence in future clinical or commercial milestones.

The company maintains a zero debt-to-equity ratio, ranking in the top quartile among pharmaceutical peers and minimizing leverage risk.

High liquidity and dilution risks threaten shareholder value, as the company faces significant challenges in maintaining adequate cash reserves.

The firm generated zero revenue in FY2025, indicating a complete lack of commercial product sales to offset substantial operating losses.

Return on equity of -4.3% places the company in the bottom quartile of the pharmaceutical cohort, reflecting poor capital efficiency.

A current ratio of 0.7 indicates severe short-term liquidity constraints, raising concerns about the ability to meet immediate obligations.

Net income deteriorated to -$62.9 million in FY2024, highlighting significant volatility and increasing financial pressure on the balance sheet.

Revenue $0.00; Operating income -$5.2M.

• ▍Revenue $0.00
• ▍Operating income -$5.2M

Revenue $0.00; Operating income -$18.0M.

• ▍Revenue $0.00
• ▍Operating income -$18.0M

Revenue $0.00; Operating income -$12.5M.

• ▍Revenue $0.00
• ▍Operating income -$12.5M

Revenue $0.00; Operating income -$50.6M.

• ▍Revenue $0.00
• ▍Operating income -$50.6M

Revenue $0.00; Operating income -$65.1M.

• ▍Revenue $0.00
• ▍Operating income -$65.1M

Revenue $0.00; Operating income -$65.1M.

• ▍Revenue $0.00
• ▍Operating income -$65.1M

Revenue $0.00; Operating income -$16.3M.

• ▍Revenue $0.00
• ▍Operating income -$16.3M

Revenue $0.00; Operating income -$16.3M.

• ▍Revenue $0.00
• ▍Operating income -$16.3M